Ensuring strategy implementation through enhanced expertise and stability in management

With the vision announced in August 2014 of the division of the Group into two independent listed companies, Galenica entered a very significant but also sensitive phase. In order to prepare the division that is planned for the next two to four years in the best possible way and to ensure implementation of the strategy, the Board of Directors will propose to the shareholders at the Annual General Meeting on 7 May 2015 the election of two new Board members:

Marc de Garidel, Chairman of the Board of Directors and CEO of Ipsen, France, as well as Romeo Cerutti, member of the Executive Board and General Counsel of Credit Suisse Group Ltd., Switzerland. With the election of new members Marc de Garidel and Romeo Cerutti, who bring with them many years of international experience in the areas of pharmaceuticals and finance, the Galenica Board of Directors will be enhanced.


Furthermore, the Board of Directors wants to ensure that the Group's strategy is implemented consistently also through stability in management. Therefore the Board of Directors has agreed a new contract with Etienne Jornod until the 2020 Annual General Meeting.

Read more02

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).

  • Download PDF03
distributed by